Close Menu
News & Commentaries
About Us
RSS
Contact
Cancel!
Privacy
Every record has been destroyed or falsified, every book rewritten, every picture has been repainted, every statue and street and building has been renamed, every date has been altered. And the process is continuing day by day and minute by minute. History has stopped. Nothing exists except an endless present in which the party is always right.
George Orwell, he/his/him
Wokeistan
Wokeistan
Diversifying the Progressive Echo Chamber
ALL BLACK LIVES MATTER!
News & Commentaries
About Us
Cancel!
RSS
Contact
Open Menu
< Back to Page
WHO Information Notice
January 20, 2021

Blessed day of January 20: WHO changes COVID guidelines

With Biden President, it'll be harder to be declared COVID-positive!



Nucleic acid testing (NAT) technologies that use polymerase chain reaction (PCR) for detection of SARS-CoV-2

20 January 2021 Medical product alert
Geneva

Product type: Nucleic acid testing (NAT) technologies that use polymerase chain reaction (PCR) for detection of SARS-CoV-2

Date: 13 January 2021

WHO-identifier: 2020/5, version 2

Target audience: laboratory professionals and users of IVDs.

Purpose of this notice: clarify information previously provided by WHO. This notice supersedes WHO Information Notice for In Vitro Diagnostic Medical Device (IVD) Users 2020/05 version 1, issued 14 December 2020.

Description of the problem: WHO requests users to follow the instructions for use (IFU) when interpreting results for specimens tested using PCR methodology.

Users of IVDs must read and follow the IFU carefully to determine if manual adjustment of the PCR positivity threshold is recommended by the manufacturer.

WHO guidance Diagnostic testing for SARS-CoV-2 states that careful interpretation of weak positive results is needed (1). The cycle threshold (Ct) needed to detect virus is inversely proportional to the patient's viral load. Where test results do not correspond with the clinical presentation, a new specimen should be taken and retested using the same or different NAT technology.

WHO reminds IVD users that disease prevalence alters the predictive value of test results; as disease prevalence decreases, the risk of false positive increases (2). This means that the probability that a person who has a positive result (SARS-CoV-2 detected) is truly infected with SARS-CoV-2 decreases as prevalence decreases, irrespective of the claimed specificity.

Most PCR assays are indicated as an aid for diagnosis, therefore, health care providers must consider any result in combination with timing of sampling, specimen type, assay specifics, clinical observations, patient history, confirmed status of any contacts, and epidemiological information.

Actions to be taken by IVD users:

Please read carefully the IFU in its entirety.
Contact your local representative if there is any aspect of the IFU that is unclear to you.
Check the IFU for each incoming consignment to detect any changes to the IFU.
Provide the Ct value in the report to the requesting health care provider.
Newer News
Older News
Privacy
© Wokeistan.com 2020